Development of docetaxel liposome surface modified with CD133 aptamers for lung cancer targeting

References

• Parkin DM, Bray F, Ferlay J, et al. Global Cancer Statistics, 2002. CA Cancer J Clin. 2005;55:74–108.
   PubMed Web of Science ®Google Scholar
• Rosell R, Felip E, Garcia-Campelo R, et al. The biology of non-small-cell lung cancer: identifying new targets for rational therapy. Lung Cancer. 2004;46:135–148.
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132.
   PubMed Web of Science ®Google Scholar
• Harper E, Dang WB, Lapidus RG, et al. Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice. Clin Cancer Res. 1999;5:4242–4248.
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Suda K, Wiens J, et al. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 2016;388:1012–1124.
   PubMed Web of Science ®Google Scholar
• Popper HH. Progression and metastasis of lung cancer. Cancer Metastasis Rev. 2016;35:75–91.
   PubMed Web of Science ®Google Scholar
• Burris HA. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. Oncogene. 2009;28:S4–S13.
   PubMed Web of Science ®Google Scholar
• Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;355:1253–1261.
   PubMed Web of Science ®Google Scholar
• Gao J, Li W, Guo Y, et al. Nanomedicine strategies for sustained, controlled and targeted treatment of cancer stem cells. Nanomedicine (Lond). 2016;11:3261–3282.
   PubMed Web of Science ®Google Scholar
• Xie F, Xu W, Yin C, et al. Nanomedicine strategies for sustained, controlled, and targeted treatment of cancer stem cells of the digestive system. WJGO. 2016;8:735–744.
   Web of Science ®Google Scholar
• Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells—perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006;66:9339–9344.
   PubMedGoogle Scholar
• Lundin A, Driscoll B. Lung cancer stem cells: progress and prospects. Cancer Lett. 2013;338:89–93.
   PubMed Web of Science ®Google Scholar
• Bertolini G, Roz L, Perego P, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA. 2009;106:16281–16286.
   PubMed Web of Science ®Google Scholar
• Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008;15:504–514.
   PubMed Web of Science ®Google Scholar
• Akbal Ö, Erdal E, Vural T, et al. Comparison of protein- and polysaccharide-based nanoparticles for cancer therapy: synthesis, characterization, drug release, and interaction with a breast cancer cell line. Artif Cells Nanomed Biotechnol. 2017;45:193–203.
   PubMed Web of Science ®Google Scholar
• Park BW, Zhuang J, Yasa O, et al. Multifunctional bacteria-driven microswimmers for targeted active drug delivery. ACS Nano. 2017;11:8910–8923.
   PubMed Web of Science ®Google Scholar
• Li S, Wang XP. In vitro and in vivo evaluation of novel NGR-modified liposomes containing brucine. IJN. 2017;12:5797–5804.
   Web of Science ®Google Scholar
• Johnsen KB, Burkhart A, Melander F, et al. Targeting transferrin receptors at the blood–brain barrier improves the uptake of immunoliposomes and subsequent cargo transport into the brain parenchyma. Sci Rep. 2017;7:10396.
   PubMed Web of Science ®Google Scholar
• Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov. 2010;9:537–550.
   PubMed Web of Science ®Google Scholar
• Shigdar S, Qiao L, Zhou SF, et al. RNA aptamers targeting cancer stem cell marker CD133. Cancer Lett. 2013;330:84–95.
   PubMed Web of Science ®Google Scholar
• Du N, Song L-P, Li X-S, et al. Novel pH-sensitive nanoformulated docetaxel as a potential therapeutic strategy for the treatment of cholangiocarcinoma. J Nanobiotechnol. 2015;13:17.
   PubMed Web of Science ®Google Scholar
• Blumenthal GM, Scher NS, Cortazar P, et al. First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Clin Cancer Res. 2013;19:4911–4916.
   PubMed Web of Science ®Google Scholar
• Gao J, Liu W, Xia Y, et al. The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. Biomaterials. 2011;32:3459–3470.
   PubMed Web of Science ®Google Scholar
• Gao J, Sun J, Li H, et al. Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing. Biomaterials. 2010;31:2655–2664.
   PubMed Web of Science ®Google Scholar
• Chowdhury S, Burbridge S, Harper PG. Chemotherapy for the treatment of hormone-refractory prostate cancer. Int J Clin Pract. 2007;61:2064–2070.
   PubMed Web of Science ®Google Scholar
• Fulton B, Spencer CM. Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs. 1996;51:1075–1092.
   PubMed Web of Science ®Google Scholar
• Azargoon A, Negahdari B. Lung regeneration using amniotic fluid mesenchymal stem cells. Artif Cells Nanomed Biotechnol. 2017; 4:1–5.
   Web of Science ®Google Scholar
• Islami M, Mortazavi Y, Soleimani M, et al. In vitro expansion of CD 133+ cells derived from umbilical cord blood in poly-l-lactic acid (PLLA) scaffold coated with fibronectin and collagen. Artif Cells Nanomed Biotechnol. 2017;6:1–9.
   Web of Science ®Google Scholar